# Jonathan D. Schwartz

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jonathan-d-schwartz/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,255 |
| Field | Hepatocellular Carcinoma Treatment and Prognosis |
| h-index | 30 |
| i10-index | 48 |
| Last Known Institution | Eternity Bioscience (United States) |
| OpenAlex ID | https://openalex.org/A5087072984 |
| ORCID iD | 0000-0002-2211-4151 |
| Works | 106 |

## Researcher papers

- [Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-patients-with/)
- [Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-monotherapy-for-previously-treated-advanced-gastric-or-gastro/)
- [Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial](https://scholariq.org/papers/ramucirumab-versus-placebo-as-second-line-treatment-in-patients-with-advanced/)
- [Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma](https://scholariq.org/papers/phase-ii-trial-evaluating-the-clinical-and-biologic-effects-of-bevacizumab-in/)
- [Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis](https://scholariq.org/papers/recurrence-of-hepatocellular-carcinoma-after-liver-transplant-patterns-and/)
- [Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials](https://scholariq.org/papers/neoadjuvant-and-adjuvant-therapy-for-resectable-hepatocellular-carcinoma-review/)
- [Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/<i>neu</i>](https://scholariq.org/papers/herceptin-and-gemcitabine-for-metastatic-pancreatic-cancers-that-overexpress-her/)
- [Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia](https://scholariq.org/papers/successful-engraftment-of-gene-corrected-hematopoietic-stem-cells-in-non/)
- [A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer](https://scholariq.org/papers/a-phase-ii-and-biomarker-study-of-ramucirumab-a-human-monoclonal-antibody/)
- [Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial](https://scholariq.org/papers/ramucirumab-combined-with-folfox-as-front-line-therapy-for-advanced-esophageal/)
- [Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal](https://scholariq.org/papers/gene-therapy-for-infantile-malignant-osteopetrosis-review-of-pre-clinical/)

## Researcher topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [DNA Repair Mechanisms](https://scholariq.org/topics/dna-repair-mechanisms/)
- [CRISPR and Genetic Engineering](https://scholariq.org/topics/crispr-and-genetic-engineering/)
- [Angiogenesis and VEGF in Cancer](https://scholariq.org/topics/angiogenesis-and-vegf-in-cancer/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Eternity Bioscience (United States)](https://scholariq.org/institutions/eternity-bioscience-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.